Publications by authors named "Sergey Zhuravel"
Background: Nafamostat, a serine protease inhibitor, has been used for the treatment of disseminated intravascular coagulation and pancreatitis. In vitro studies and clinical reports suggest its beneficial effect in the treatment of COVID-19 pneumonia.
Methods: This phase 2 open-label, randomised, multicentre, controlled trial evaluated nafamostat (4.
Clinical trials of thermoheliox application (inhalation with a high-temperature mixture of oxygen and helium, 90 °C) in the treatment of the acute phase of coronavirus infection were conducted. Dynamics of disease development in infected patients (PCR test for the virus) and, dynamics of changes in blood concentration of C-reactive protein, immunoglobulin M, specific immunoglobulin G were studied. High efficiency of thermoheliox in releasing the organism from the virus and stimulating the immune response (thermovaccination effect) was shown.
View Article and Find Full Text PDFExtracorporeal membrane oxygenation (ECMO) is increasingly used to treat severe cases of acute respiratory or cardiac failure. Hemorrhagic complications represent one of the most common complications during ECMO, and can be life threatening. The purpose of this study was to elucidate pathophysiological mechanisms of ECMO-associated hemorrhagic complications and their impact on standard and viscoelastic coagulation tests.
View Article and Find Full Text PDFArticle Synopsis
- In Russia and Sweden, the study evaluated the effectiveness of sofosbuvir/velpatasvir, a pangenotypic treatment, in patients with hepatitis C virus (HCV) genotypes 1, 2, or 3 over a 12-week period.
- Out of 119 treated patients, the overall sustained virologic response rate was an impressive 99%, indicating the treatment’s high efficacy.
- The treatment was found to be safe and well-tolerated, with only mild side effects reported, such as headache and fatigue, and no patients discontinuing treatment due to adverse events.
Introduction: The objective of the study was to evaluate the prevalence of Clostridium difficile-associated diarrhoea (CDAD) among hospitalised patients with antibiotic-associated diarrhoea (AAD) in general and by specific types of medical care and hospital units.
Methods: A prospective, cross-sectional, non-interventional, multicentre study. The main inclusion criteria were: patient age ≥ 18 years, hospital stay of at least 48 h, current antibiotic therapy or antibiotic therapy within the previous 30 days, loose stools (Bristol stool types 5-7 and stool frequency ≥ 3 within ≤ 24 consecutive hours or exceeding normal for the patient) and signed informed consent form.